MCE 补体系统相关蛋白 Complement System Related Proteins

MCEMasterofBioactiveMolecules补体系统相关蛋白补体系统(ComplementSystem)是先天免疫的主要成分之一，由可溶性血浆蛋白、膜型补体调节蛋白和补体受体组成，存在于血浆、组织、细胞表面，甚至细胞内。补体系统主要有三条激活途径：经典途径(CP)、凝集素途径(LP)、旁路途径(AP)。这些途径依赖不同的起始分子激活，但最后产生相同的终端效应分子：过敏性毒素(C4a/C3a/C5a)、膜攻击复合物(MAC)和调理素(如C3b)。补体系统在防御病原体和维持宿主稳态中起着关键作用[29]。ComplementSystemClassicalPathwayLectinPathwayC1qMBLAg-AbComplexesLectinBindsMannoseonPathogensC1,MASPsC4,C4C2C2CR1C3ConvertaseFcRC3C3bOpsonizationC5ConvertasePhagocytosisC5C5bC6,C7,C8C9C5b-9

AlternativePathwayPathogens,InjuredTissueC3bC3bC3aRC3aC5aRInflammationC3aRC5aC5aRMACCellLysisandActivationFigure8.三种补体系统激活途径[30]Cat.No.ProductNameSpeciesSourceTagHY-P7863ComplementC3/C3aMouseE.coliTag-freeHY-P7864ComplementC5/C5aHumanE.coliTag-freeHY-P70031CFHR2HumanMammalianCellsC-HisHY-P70055CFHR1HumanMammalianCellsC-HisHY-P70102CFHR5HumanMammalianCellsC-HisHY-P7692HABP1/C1QBPHumanE.coliC-HisHY-P71718C1QAMouseP.pastorisN-HisHY-P71423VSIG4HumanMammalianCellsC-FcHY-P75395CD55/DAFHumanMammalianCellsC-HisHY-P7890ComplementfactorH/CFHHumanMammalianCellsC-HisHY-P74371C7/ComplementcomponentC7HumanMammalianCellsC-HisHY-P74375C2/ComplementC2HumanMammalianCellsC-HisHY-P74614ProteinS/PROS1HumanMammalianCellsC-HisHY-P75463C1s-AsubcomponentMouseMammalianCellsC-HisHY-P75464C1QBHumanSf9InsectCellsC-His11www.MedChemEInhibitors • ScreeningLibraries • ProteinsMCE重组蛋白MCE重组蛋白产品种类丰富，涵盖细胞因子、病毒蛋白、免疫检查点蛋白、CAR-T蛋白、CD抗原、受体蛋白、生物素标记蛋白、GMP级蛋白、酶等多种分类，可用于人、病毒、小鼠、大鼠、猴、猪、狗、牛、羊、兔、猫、非洲爪蟾等多个物种不同研究领域的生物学研究，包括蛋白结构研究、免疫检测试剂、重组蛋白药物、诊断试剂开发、抗体药物靶点、CAR-T细胞治疗靶点、Fc受体、流感病毒蛋白和细胞因子等热门研究领域。MCE因高品质的产品和优质的售前售后服务，成为全球数百万计的科学家和技术人员值得信赖的实验伙伴。产品种类丰富： 细胞因子和生长因子、免疫检查点蛋白、CAR-T相关蛋白、CD抗原、受体蛋白、酶&调节子、补体系统蛋白、病毒类蛋白、生物素标记蛋白、荧光标记蛋白、GMP级蛋白,泛素相关蛋白等产品物种多样性：人、病毒、小鼠、大鼠、猴、猪、狗、牛、羊、兔、猫、非洲爪蟾、细菌、真菌等低内毒素水平： LAL法验证，内毒素含量低于绝大多数供应标准高纯度： SDS和HPLC检测验证高生物活性： 相关体内/体外生物学实验测定稳定的一致性： 多批次检测数据确认规格齐全： 满足客户的多种预分装规格高纯度ThepurityofhumanBMP-2isgreaterthan95%asanalyzedbySDSunderreducing(R)andnon-reducing(N)condition.kDa M R 120806040302010卓越的批间稳定性TheED50ofMCEhumanVEGF165fromthreedifferentLotsaresimilar.1.0Lot1nm)0.8Lot20.6Lot3(4900.4OD0.2Net0.01010101010VEGF165,Human(ng/mL)

高活性HumanGM-CSFstimulatescellproliferationofTF-1cellswithanED50oflessthan0.5ng/mL.2.0(490nm)1.51.0NetOD0.50.010101010101010GM-CSF,Human(ng/mL)竞品对比TheED50ofhumanVEGF165fromMCE’seachLotislowerthanofCompetitorP.1.0BrandPnm)0.8Lot20.6Lot3(4900.4OD0.2Net0.010-210-1101010VEGF165,Human(ng/mL)MCEMasterofBioactiveMoleculesPublicationsCitingUseofMCEProductsNature.2023Jun;618(7964):374-382.Nature.2023Jun;618(7966):862-870.Nature.2023Jun;618(7965):590-597.Nature.2023Jun;618(7963):180-187.Nature.2023May;617(7962):818-826Science.2023Jun9;380(6649):eabo2296.Science.2022Dec2;378(6623):eabo5503.Science.2022Nov18;378(6621):eabq7361.Science.2022Oct14;378(6616):eabq0132.Science.2022Jul8;377(6602):eabg9302Cell.2023Jun22;186(13):2823-2838.e20.Cell.2023May11;186(10):2144-2159.e22.Cell.2023Mar30;186(7):1352-1368.e18.Cell.2023Mar2;186(5):1026-1038.e20.Cell.2023Feb16;186(4):850-863.e16MCEGlobalPartnersMCEMasterofBioactiveMolecules客户验证诱导小鼠肺成纤维细胞纤维化TGF-β1(HY-P7117)刺激原代小鼠肺成纤维细胞，通过qRT-PCR和WB检测PTPN13和NOX4表达水平，确定其与细胞纤维化密切相关[41]。ControlTGF-β1PTPN13NOX4expression10**expression8**86mRNA6mRNA44Relative2Relative200

ControlTGF-β1ControlTGF-β1CollagenI139kDaPTPN13310kDaα-SMA42kDaNOX455kDaGAPDH37kDaGAPDH37kDa构建肾脏类器官从小鼠肾脏组织中提取细胞，利用微流体技术结合3D打印机制作类器官珠，辅以Noggin(HY-P7086)、R-spondin-1(HY-P7114)、FGF-4(HY-P7014)、FGF-basic(HY-P7066)、SB-431542(HY-10431)、Laduviglusib(HY-10182)培养，7天后，得到数千个大小、形状和成分具有高度重复性的肾脏类器官[42]。OrganoidGeneratingKidneyOrganoidBeadsKidneyOrganoidsMatrigel+CellsDay1Day7QDs/Drugs7days24hrsOrganoidCulturingCulturingHighThroughputScreeningOil4°CKidneyOrganoidBeads200μm200μmCultureDish37°CIFN-γ诱导蛋白16(IFI16)的积累通过Westernblotting检测IFN-γ(HY-P7025)处理人肺腺癌上皮(A549)细胞18小时后，蛋白16(IFI16)的积累，通过免疫染色检测IFN-γ诱导16小时后IFI16的细胞定位[43]。HumanIFN-γ(ng/mL)0505001000IFI16—100(kDa)—70β-actin—40

NegativeControl IFN-γ(500ng/mL)DAPI/IFI1617www.MedChemEInhibitors • ScreeningLibraries • Proteins更多文献引用情况文献产品名称货号AdvFunctMater.10March2022.IFN-gamma;IL-13;IL-4HY-P7071;HY-P7076A;HY-P7080SignalTransductTargetTher.2022Mar11;7(1):83.AXLHY-P7622SignalTransductTargetTher.2022Jan7;7(1):6.HABP2HY-P70832NatMicrobiol.2021Jul;6(7):932-945.IFN-gammaHY-P7025AdvSci(Weinh).2021Dec;8(24):e2100808.NPYHY-P71063CellDeathDiffer.2022Apr;29(4):818-831.FGFbasic;FGF-2HY-P7004;HY-P7066NatCommun.2022Feb23;13(1):1017.TGFbeta1HY-P7118JImmunotherCancer.2022Feb;10(2):e003716.IL-2HY-P7077Small.2020Jun;16(22):e2001371.FGF-4;FGF-2;Noggin;RSPO1HY-P7014;HY-P7066;HY-P7086;HY-P7114Biomaterials.2021Jan;265:120392.GM-CSFHY-P7069RedoxBiol.2021Jul;43:101994.IL-6HY-P7103ATheranostics.2022Jan1;12(3):1097-1116.IGF2HY-P7019Theranostics.2022Jan1;12(2):747-766.IFN-gammaHY-P7025;HY-P7071Theranostics.2021May13;11(14):7110-7125.TGFbeta1HY-P7118Theranostics.2021Jan9;11(7):3244-3261.TGFbeta1HY-P7117ActaPharmSinB.2020Sep;10(9):1619-1633.M-CSFHY-P7085JExpClinCancerRes.2020Jun23;39(1):119.IL-6RalphaHY-P7223BiosensBioelectron.2020Sep19;173:112619.IFN-gammaHY-P7025CardiovascDiabetol.2022Feb15;21(1):25.AsprosinHY-P7612JControlRelease.IL-4;M-CSF;TNF-alpha;HY-P7080;HY-P7085;HY-P7090;2021Jul26;S0168-3659(21)00383-7.MIP-1alpha;GM-CSFHY-P7255;HY-P7361CellRep.2022Feb1;38(5):110319.TNFalpha;GMPIL-6HY-P70426;HY-P7044GCellRep.2021Jan5;34(1):108576.IL-1RAHY-P7029ACellRep.2020Jan7;30(1):98-111.e5.FGFbasic;EGF;VEGF121HY-P7004;HY-P7109;HY-P7420ActaBiomater.2020Jan1;101:152-167.DKK-1HY-P7155ACancerLett.2022Mar9;215629.BDNFHY-P7116ACancerLett.13July2021.FGFbasicHY-P7004CellDeathDis.2021Apr14;12(4):397.NRG1-beta1HY-P7365CellDeathDis.2021Nov27;12(12):1113.FGFbasicHY-P7004CellDeathDis.2021Oct12;12(10):934.M-CSFHY-P7085CellDeathDis.2020May7;11(5):323.TNF-alphaHY-P7416CellDeathDis.2020Nov4;11(11):950.Insulin;FGFbasic;EGFHY-P0035;HY-P7004;HY-P7109JNeuroinflammation.2019Nov26;16(1):234.IL-1RAHY-P702918MCEMasterofBioactiveMoleculesReferences:Jun-MingZhang.Cytokines,inflammation,andpain.IntAnesthesiolClin.2007Spring;45(2):27-37.PedroBerraondo,etal.Cytokinesinclinicalcancerimmunotherapy.BrJCancer.2019Jan;120(1):6-15.Ferreira,Vinicius,etal.CytokinesandInterferons:TypesandFunctions.InAutoantibodiesandCytokines,editedbyWahidKhan.London:IntechOpen,2018.XiaochenRen,etal.GrowthFactorEngineeringStrategiesforRegenerativeMedicineApplications.FrontBioengBiotechnol.2019;7:469.StoneWL,LeavittL,VaracalloM.Physiology,GrowthFactor.In:StatPearls[Internet].TreasureIsland(FL):StatPearlsPublishing;2022Jan.OzlemGuzeloglu-Kayisli,HughSTaylor,etal.Theroleofgrowthfactorsandcytokinesduringimplantation:endocrineandparacrineinteractions.SeminReprodMed.2009Jan;27(1):62-79.YapingZhang,etal.FunctionsofImmuneCheckpointMoleculesBeyondImmuneEvasion.AdvExpMedBiol.2020;1248:201-226.XingHe,etal.Immunecheckpointsignalingandcancerimmunotherapy.CellResearch.2020;30:660-669.Marin-AcevedoJA,etal.Nextgenerationofimmunecheckpointtherapyincancer:newdevelopmentsandchallenges.JHematolOncol.2018;11(1):39.ChristopherDeRenzo,etal.GeneticModificationStrategiestoEnhanceCARTCellPersistenceforPatientsWithSolidTumors.FrontImmunol.2019Feb15;10:218.MEssand,etal.GeneticallyengineeredTcellsforthetreatmentofcancer.JInternMed.2013Feb;273(2):166-81.ZhenguangWang,etal.NewdevelopmentinCAR-Tcelltherapy.JHematolOncol.2017;10:53.LekhaMikkilineni,etal.ChimericantigenreceptorT-celltherapiesformultiplemyeloma.Blood.2017Dec14;130(24):2594-2602.JuliusM.Cruse,RobertE.Lewis,andHuanWang.CLUSTEROFDIFFERENTIATION(CD)ANTIGENS.ImmunologyGuidebook.2004:47-124.TomasKalina,etal.CDMaps-DynamicProfilingofCD1-CD100SurfaceExpressiononHumanLeukocyteand[16]LymphocyteSubsets.FrontImmunol.2019Oct23;10:2434.DarioGosmann,AngelaM.Krackhardt,CalogeroD’Alessandria,etal.P.romiseandchallengesofclinicalnon-invasiveT-celltrackingintheeraofcancerimmunotherapy.EJNMMIRes.2022Jan31;12(1):5.MareeS.etal.FcReceptors.AdvExpMedBiol.2008;640:22-34.SanaeBenMkaddem,etal.UnderstandingFcReceptorInvolvementinInflammatoryDiseases:FromMechanismstoNewTherapeuticTools.FrontImmunol.2019Apr12;10:811.D.Mancardi.FcReceptor-DependentImmunity.ReferenceModuleinBiomedicalSciences.2014:B978-0-12-801238-3.00119-7.Mårtensson,A.DevelopmentofanAntigen-independentAffinityAssaytoStudytheBindingofIgGtoFcGammaReceptors.2012.S.Xiong,etal.HumanImmuneSystem,Editor(s):Andersrahme,ComprehensiveBiomedicalPhysics,Elsevier,2014,Pages91-114.Carl-HenrikHeldin,etal.SignalsandReceptors.ColdSpringHarbPerspectBiol.2016Apr;8(4):a005900.RitaSantos,etal.Acomprehensivemapofmoleculardrugtargets.NatRevDrugDiscov.2017Jan;16(1):19-34..

Young-SunLee,etal.Anti-InflammatoryEffectsofGLP-1-BasedTherapiesbeyondGlucoseControl.MediatorsInflamm.2016;2016:3094642.PeterK.etal.Enzymes:principlesandbiotechnologicalapplications.EssaysBiochem.2015Nov15;59:1-41.AntonioBlanco,etal.Enzymes,Editor(s):AntonioBlanco,Gustavolanco,MedicalBiochemistry,AcademicPress,2017,Pages153-175.CooperGM.TheCell:AMolecularApproach.2ndedition.Sunderland(MA):SinauerAssociates;2000.LiubovPoshyvailo.Modellingandsimulationsofenzyme-catalyzedreactions.NationalUniversityof“Kyiv-MohylaAcademy”FacultyofNaturalSciences,DepartmentofPhysicsandMathematics.2015.JanewayCAJr,etal.Thecomplementsystemandinnateimmunity.Immunobiology:TheImmuneSysteminHealthandDisease.5thedition.NewYork:GarlandScience;2001.GuillerminaGirardi,etal.EssentialRoleofComplementinPregnancy:FromImplantationtoParturitionandBeyond.FrontImmunol.2020;11:1681.LanKNguyen,etal.Whenubiquitinationmeetsphosphorylation:asystemsbiologyperspectiveofEGFR/MAPKsignaling.CellCommunSignal.2013Jul31;11:52.GuoHJ,etal.Biochemistry,Ubiquitination.In:StatPearls[Internet].TreasureIsland(FL):StatPearlsPublishing;2022Jan.FuShang,etal.Ubiquitin-proteasomepathwayandcellularresponsestooxidativestress.FreeRadicBiolMed.2011Jul1;51(1):5-16.Hochstrasser,M.Originandfunctionofubiquitin-likeproteins.Nature.2009Mar26;458(7237):422-9.ViralStructuralProteins.NCBI.Literature.MeSHDatabase.Yearintroduced:1990.JenniferLouten.VirusStructureandClassification.EssentialHumanVirology.2016:19-29.GelderblomHR.StructureandClassificationofViruses.In:BaronS,editor.MedicalMicrobiology.4thedition.Galveston(TX):UniversityofTexasMedicalBranchatGalveston;1996.Chapter41.ChandraMohan,etal.ABriefStudyonRateofMorphologicalandGenomicSimilaritiesb